Session

IBD: Mixed trials

DIET-INDUCED REMISSION IN PEDIATRIC CROHN'S DISEASE IS ASSOCIATED WITH A MARKED DECREASE OF KYNURENINE, A TRYPTOPHAN METABOLITE ASSOCIATED WITH INFLAMMATION

Mohammed Ghiboub

DIET-INDUCED REMISSION IN PEDIATRIC CROHN'S DISEASE IS ASSOCIATED WITH A MARKED DECREASE OF KYNURENINE, A TRYPTOPHAN METABOLITE ASSOCIATED WITH INFLAMMATION

Mohammed Ghiboub, Charlotte M. Verburgt, Susanne Penny, Arie Levine, Rotem Sigall Boneh, Eytan Wine, Alejandro Cohen, Katherine A Dunn, Devanand Pinto, Marc A. Benninga, Wouter J. de Jonge, Johan van Limbergen

EFFICACY AND SAFETY OF ADALIMUMAB IN PEDIATRIC PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS: RESULTS OF A RANDOMIZED-CONTROLLED PHASE 3 STUDY

Nicholas M. Croft

EFFICACY AND SAFETY OF ADALIMUMAB IN PEDIATRIC PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS: RESULTS OF A RANDOMIZED-CONTROLLED PHASE 3 STUDY

Nicholas M. Croft, William A Faubion, Subra Kugathasan, Jaroslaw Kierkuś, Frank Ruemmele, Nael M. Mostafa, Mary Venetucci, Tricia Finney-Hayward, Mareike Bereswill, Andreas Lazar, Dan Turner

INCREASING USE OF BIOLOGICS DID NOT REDUCE HOSPITALIZATION AND SURGERY RATES IN PAEDIATRIC IBD: A POPULATION-BASED STUDY FROM THE EPI-IIRN DATABASE

Gili Focht

INCREASING USE OF BIOLOGICS DID NOT REDUCE HOSPITALIZATION AND SURGERY RATES IN PAEDIATRIC IBD: A POPULATION-BASED STUDY FROM THE EPI-IIRN DATABASE

Dan Turner, Noa Asayag, Adi Mendelovici, Gili Focht, Eran Matz, Amos Cahan, Natan Ledderman, Ziona Haklai, Iris Dotan, Yehuda Chowers

SINGLE-CELL TRANSCRIPTOMICS IN PERIPHERAL BLOOD MONONUCLEAR CELLS REVEALS CELL POPULATION DIFFERENCES THAT DEFINE VEDOLIZUMAB RESPONSE AMONG CD PATIENTS

Andrew Y.F. Li Yim

SINGLE-CELL TRANSCRIPTOMICS IN PERIPHERAL BLOOD MONONUCLEAR CELLS REVEALS CELL POPULATION DIFFERENCES THAT DEFINE VEDOLIZUMAB RESPONSE AMONG CD PATIENTS

Andrew Y.F. Li Yim, Ishtu Hageman, Vincent Joustra, Marcel M.A.M. Mannens, Geert R. D'Haens, Wouter J. de Jonge, Peter Henneman

TREATMENT OUTCOME OF TOFACITINIB DOSE REDUCTION TO 5 MG BID VS REMAINING ON 10 MG BID IN PATIENTS WITH UC WHO WERE IN STABLE REMISSION ON 10 MG BID: 6-MONTH DATA FROM THE DOUBLE-BLIND, RANDOMISED RIVETING STUDY

Severine Vermeire

TREATMENT OUTCOME OF TOFACITINIB DOSE REDUCTION TO 5 MG BID VS REMAINING ON 10 MG BID IN PATIENTS WITH UC WHO WERE IN STABLE REMISSION ON 10 MG BID: 6-MONTH DATA FROM THE DOUBLE-BLIND, RANDOMISED RIVETING STUDY

Severine Vermeire, Chinyu Su, Nervin Lawendy, Taku Kobayashi, William Sandborn, David T. Rubin, Irene Modesto, Sean Gardiner, nicole kulisek, Haiying Zhang, Wenjin Wang, Julian Panés

Item 1 - 10 / 10
1